POS-354 WORSENING KIDNEY DISEASE INFLUENCES THE EFFICACY OF ERTUGLIFLOZIN ON GLUCOSURIA-MEDIATED ENDPOINTS BUT DOES NOT INFLUENCE THE EFFICACY ON NATRIURESIS-RELATED ENDPOINTS: PRESPECIFIED ANALYSES FROM VERTIS CV

Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor approved for the treatment of adults with type 2 diabetes mellitus (T2DM). We report results from prespecified exploratory analyses assessing effects of ertugliflozin on presumptive glucosuria-mediated and natriuresis/diuresis-mediated endpoints by the Kidney Disease Improving Global Outcomes in Chronic Kidney Disease (KDIGO CKD) risk categories from the phase III, double-blind, placebo-controlled cardiovascular (CV) outcomes study (VERTIS CV; NCT01986881).